Predicting treatment response in patients with HFpEF and myocardial fibrosis. Identifying useful tools with the help of CMR
Authors:
- 6 August 2022
- journal article
- editorial
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 38 (10) , 2209-2211
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2019
- Heart Failure With Preserved, Borderline, and Reduced Ejection FractionJACC, 2017
- Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection FractionJAMA Cardiology, 2017
- Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection FractionJACC, 2016
- T1-mapping in the heart: accuracy and precisionJournal of Cardiovascular Magnetic Resonance, 2014
- Spironolactone for Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2014
- Analysing Recurrent Hospitalizations in Heart Failure: A Review of Statistical Methodology, with Application to CHARM-PreservedEuropean Journal of Heart Failure, 2013
- Cardiac Magnetic Resonance Postcontrast T1 Time Is Associated With Outcome in Patients With Heart Failure and Preserved Ejection FractionCirculation: Cardiovascular Imaging, 2013
- Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial FibrosisCirculation, 2010
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003